载VEGF二氧化硅超颗粒用于胚胎培养的初步研究
本研究在小鼠模型中评估载血管内皮生长因子(VEGF)的二氧化硅超颗粒(V-SPs)作为胚胎培养液添加物的效果。V-SPs可缓释VEGF,使囊胚总细胞数显著增加,效果与游离VEGF相当,冻干后仍有效。提示V-SPs是向体外胚胎递送生物活性VEGF的潜在新方法。
要点
- V-SPs缓释VEGF可促进小鼠囊胚发育,效果与游离VEGF等效。
- V-SPs冻干后仍保持生物活性,便于储存。
- V-SPs可能避免VEGF在溶液中稳定性差的问题。
核心结论
- V-SPs可替代游离VEGF用于胚胎培养,促进胚胎发育。
研究设计与样本
- 实验室研究,使用小鼠模型,V-SPs体外制备并添加至胚胎培养液。
主要发现
- V-SPs释放VEGF呈初始突释后48小时持续低水平释放。
- V-SPs使囊胚总细胞数较对照显著增加(P < 0.001),与新鲜游离VEGF效果相当(P < 0.001)。
- 冻干V-SPs对胚胎发育有类似效果(P < 0.05)。
关键数值与推荐
- 小鼠胚胎在20 µl G1/G2培养液、5%氧气条件下培养,添加10 ng/ml重组小鼠VEGF或V-SPs。
临床怎么用
- V-SPs可能作为VEGF递送新方式用于体外胚胎培养,但临床IVF应用需进一步研究。
局限性
- 仅在小鼠模型中验证,尚未在人类胚胎中研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can vascular endothelial growth factor (VEGF)-loaded silica supraparticles (V-SPs) be used as a novel mode of delivering VEGF to the developing preimplantation embryo in vitro? SUMMARY ANSWER: Supplementation of embryo culture media with V-SPs promoted embryonic development in a manner equivalent to media supplemented with free VEGF. WHAT IS KNOWN ALREADY: VEGF is a maternally derived growth factor that promotes preimplantation embryonic development in vitro. However, its use in clinical media has limitations due to its low stability in solution. STUDY DESIGN, SIZE, DURATION: This study was a laboratory-based analysis utilising a mouse model. V-SPs were prepared in vitro and supplemented to embryonic culture media. The bioactivity of V-SPs was determined by analysis of blastocyst developmental outcomes (blastocyst development rate and total cell number). PARTICIPANTS/MATERIALS, SETTING, METHODS: SPs were loaded with fluorescently labelled VEGF and release kinetics were characterised. Bioactivity of unlabelled VEGF released from V-SPs was determined by analysis of embryo developmental outcomes (blastocyst developmental rate and total cell number) following individual mouse embryo culture in 20 µl of G1/G2 media at 5% oxygen, supplemented with 10 ng/ml recombinant mouse VEGF in solution or with V-SPs. The bioactivity of freeze-dried V-SPs was also assessed to determine the efficacy of cryostorage. MAIN RESULTS AND THE ROLE OF CHANCE: VEGF release kinetics were characterised by an initial burst of VEGF from loaded spheres followed by a consistent lower level of VEGF release over 48 h. VEGF released from V-SPs resulted in significant increases in total blastocyst cell number relative to the control (P < 0.001), replicating the effects of medium freely supplemented with fresh VEGF (P < 0.001). Similarly, freeze dried V-SPs exerted comparable effects on embryonic development (P < 0.05). LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: In this proof of principle study, the effects of V-SPs on embryonic development were only analysed in a mouse model. WIDER IMPLICATIONS OF THE FINDINGS: These findings suggest that SPs represent a novel method by which a targeted dose of therapeutic agents (e.g. bioactive VEGF) can be delivered to the developing in vitro embryo to promote embryonic development, an approach that negates the breakdown of VEGF associated with storage in solution. As such, V-SPs may be an alternative and effective method of delivering bioactive VEGF to the developing in vitro embryo; however, the potential use of V-SPs in clinical IVF requires further investigation. STUDY FUNDING/COMPETING INTEREST(S): This work was funded by the University of Melbourne. The authors have no conflict of interest to declare.
引用
- Gurner KH, Richardson JJ, Harvey AJ, et al. A pilot study investigating a novel particle-based growth factor delivery system for preimplantation embryo culture. Hum Reprod. 2021. PMID: 33975346. doi:10.1093/humrep/deab105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。